Literature DB >> 17855686

Standardization of steroid hormone assays: why, how, and when?

Frank Z Stanczyk1, Jennifer S Lee, Richard J Santen.   

Abstract

Lack of standardization of high-quality steroid hormone assays is a major deficiency in epidemiologic studies. In postmenopausal women, reported levels of serum 17beta-estradiol (E(2)) are highly variable and median normal values differ by approximately a 6-fold factor. A particular problem is the use of E(2) assays for prediction of breast cancer risk and osteoporotic fractures, where assay sensitivity may be the most important factor. Identification of women in the lowest categories of E(2) levels will likely provide prognostic information that would not be available in a large group of women in whom E(2) levels are undetectable by less sensitive assays. Detailed and costly methods involving extraction and chromatography in conjunction with RIA provide generally acceptable E(2) results in postmenopausal serum, whereas less tedious, direct immunoassays suffer from inadequate specificity and sensitivity. Studies comparing the two types of methods generally report higher E(2) values with the direct methods as a result of cross-reactivity with other steroids and reduced correlation with biological variables such as body mass index. Similar problems exist with measurements of E(2) and estrone in men, and estrone and testosterone in women. Interest in mass spectrometry-based assays is increasing as potential gold standard methods with enhanced sensitivity and specificity; however, these assays require costly instrumentation and highly trained personnel. Taking all of these issues into consideration, we propose establishment of standard pools of premenopausal, postmenopausal, and male serum, and utilization of these for cross-comparison of various methods on an international basis. An oversight group could then establish standards based on these comparisons and set agreed upon confidence limits of various hormones in the pools. These criteria would allow validation of sensitivity, specificity, precision, and accuracy of current steroid hormone assay methodology and provide surrogates until a true gold standard can be developed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855686     DOI: 10.1158/1055-9965.EPI-06-0765

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  51 in total

1.  The utility and dynamics of salivary sex hormone measurements in the National Social Life, Health, and Aging Project, Wave 2.

Authors:  Michael J Kozloski; L Philip Schumm; Martha K McClintock
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2014-11       Impact factor: 4.077

2.  Measuring Estrogen Exposure and Metabolism: Workshop Recommendations on Clinical Issues.

Authors:  L M Demers; S E Hankinson; S Haymond; T Key; W Rosner; R J Santen; F Z Stanczyk; H W Vesper; R G Ziegler
Journal:  J Clin Endocrinol Metab       Date:  2015-04-07       Impact factor: 5.958

3.  Pharmacokinetics and pharmacodynamics of oral and transdermal 17β estradiol in girls with Turner syndrome.

Authors:  Martha Taboada; Richard Santen; John Lima; Jobayer Hossain; Ravinder Singh; Karen Oerter Klein; Nelly Mauras
Journal:  J Clin Endocrinol Metab       Date:  2011-08-31       Impact factor: 5.958

4.  Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.

Authors:  Ping Fan; Wei Yue; Ji-Ping Wang; Sarah Aiyar; Yan Li; Tae-Hyun Kim; Richard J Santen
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

5.  Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study.

Authors:  Christy G Woolcott; Yurii B Shvetsov; Frank Z Stanczyk; Lynne R Wilkens; Kami K White; Christian Caberto; Brian E Henderson; Loïc Le Marchand; Laurence N Kolonel; Marc T Goodman
Journal:  Endocr Relat Cancer       Date:  2010-02-18       Impact factor: 5.678

6.  Liquid chromatography-mass spectrometry (LC-MS) of steroid hormone metabolites and its applications.

Authors:  Trevor M Penning; Seon-Hwa Lee; Yi Jin; Alejandro Gutierrez; Ian A Blair
Journal:  J Steroid Biochem Mol Biol       Date:  2010-01-18       Impact factor: 4.292

7.  Close correlation between hyperandrogenism and insulin resistance in women with polycystic ovary syndrome-Based on liquid chromatography with tandem mass spectrometry measurements.

Authors:  Yabo Yang; Miao Ding; Na Di; Ricardo Azziz; Dongzi Yang; Xiaomiao Zhao
Journal:  J Clin Lab Anal       Date:  2018-10-23       Impact factor: 2.352

8.  Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Authors:  Jason D Robarge; Zereunesay Desta; Anne T Nguyen; Lang Li; Daniel Hertz; James M Rae; Daniel F Hayes; Anna M Storniolo; Vered Stearns; David A Flockhart; Todd C Skaar; N Lynn Henry
Journal:  Breast Cancer Res Treat       Date:  2016-12-09       Impact factor: 4.872

9.  Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens.

Authors:  Jessica M Faupel-Badger; Barbara J Fuhrman; Xia Xu; Roni T Falk; Larry K Keefer; Timothy D Veenstra; Robert N Hoover; Regina G Ziegler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

10.  Predictors of recovery of ovarian function during aromatase inhibitor therapy.

Authors:  N L Henry; R Xia; M Banerjee; C Gersch; D McConnell; D Giacherio; A F Schott; M Pearlman; V Stearns; A H Partridge; D F Hayes
Journal:  Ann Oncol       Date:  2013-04-23       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.